The ACARE LevelUp Webinar series will consist of 6 webinars that have a 50-minute lecture with 10-min question and answer sessions. They will be hosted by some of the most esteemed physicians in the angioedema field.
These 1 hour webinars will deal with different questions and topics, which include but are not limited to guideline recommendations and updates, recent insights from publications, advances in our understanding of angioedema and the comorbidities that go along with it, biomarkers in angioedema and the biology of mast cells and the contact system including C1 inhibitor, kallikrein, bradykinin and its receptors and many more.
- REGISTER NOW for Webinar 7: ADVANCEMENTS IN GENE THERAPIES: FOCUS ON CRISPR AND HEREDITARY ANGIOEDEMA TREATMENT
- REGISTER NOW for Webinar 8: UNDERSTANDING THE DYNAMICS OF TRIGGERS AND PRODROMES IN HEREDITARY ANGIOEDEMA
- REGISTER NOW for Webinar 9: COMORBIDITIES IN HAE INCLUDING RISK OF THROMBOSIS AND AUTOIMMUNITY
- Webinar 1: HAE Case Reports Discussion from Diagnosis to Treatment
- Webinar 2: HAE with normal C1 inhibitor –
How to correctly diagnose and treat this rare type of recurrent angioedema - Webinar 3: Actual Treatment Approach in HAE : A Perspective from Different Continents with a Focus on Growth and Emerging Markets (GEMS)
- Webinar 4: Acquired angioedema: From bench to bedside.
- Webinar 5: Dissecting Molecular and Clinical Aspects of Normal C1-INH HAE
- Webinar 6: PEDIGREES IN HEREDITARY ANGIOEDEMA
Agenda
Introduction
Assistant Professor Dr. Ankur Jindal
Postgraduate Institute of Medical Education and Research, Chandigar, India
TALK 1: The current concepts behind triggers in patients with HAE: how to identify and how to manage?
Talk 15’ | Q&A 3’
Prof. Dr. Teresa Caballero, MD, PhD
Hospital Universitario La Paz, Madrid, Spain
TALK 2: Clinical implications of identification of prodromes in patients with HAE
Talk 15’ | Q&A 3’
Dr. Avner Reshef
Barzilai University Hospital, Ashkelon, Israel
TALK 3: Changes in prodromal signs in patients during the use of modern LTP
Talk 15’ | Q&A 3’
Dr. Robin Lochbaum
UIm University Hospital, Ulm, Germany
Closing remarks
Assistant Professor Dr. Ankur Jindal
Agenda
Introduction
Dr. Thomas Buttgereit
Charité – Universitätsmedizin Berlin, Institute of Allergology IFA, Fraunhofer ITMP,
Immunology and Allergology IA, Berlin, Germany
TALK 1: Comorbidities in C1 deficiency – results from an Italian survey
Talk 15’ | Q&A 3’
Dr. Andrea Zanichelli
University of Milan, I.R.C.C.S. Policlinico San Donato, Milan, Italy
TALK 2: The power of disease registries: What does the Swedish HAE registry tell us about comorbidities?
Talk 15’ | Q&A 3’
Dr. Linda Sundler Björkman
Lund University, Lund, Sweden
TALK 3: HAE and thromboembolism – is there a link and why?
Talk 15’ | Q&A 3’
Assistant Professor Dr. Steven P Grover
UNC Blood Research Center, University of North Carolina
at Chapel Hill, Chapel Hill NC, USA
Closing remarks
Dr. Thomas Buttgereit
Webinar 1: HAE Case Reports Discussion from Diagnosis to Treatment
31st January 2024, 08:30 – 09:30 am CET.
This webinar, with a focus on HAE, is designed to enable participants to:
- understand and apply cascade screening for HAE
- understand challenges in diagnosing and treating HAE in the Asia-Pacific region
- understand options for HAE prophylaxis, the risk-benefit ratio of different prophylactic options, and how to avoid/minimize risks
Topics and Faculty:
Introduction and Moderation: Dr. Ankur Jindal, India
The domino effect: unearthing HAE from one-to-many: Ridhima Aggarwal, India
HAE in the East: Addressing disparities in diagnosis and management: Dr. Philip Li, China
A Cautionary Tale: Hilary Longhurst, New Zealand
Q&A: All faculty
Webinar 2: HAE with normal C1 inhibitor –
How to correctly diagnose and treat this rare type of recurrent angioedema
April 4th, 2024, 4:00 – 5:00 pm CET.
In this webinar, participants will learn about the current definition and types of HAE with normal C1INH. The faculty will also discuss how to establish causality of an as yet undescribed mutation for angioedema.
Topics and Faculty:
Welcome and Moderation: Thomas Buttgereit, Germany
Evolving recognition of HAE-nC1INH: Anete S Grumach, Brazil
HAE-nC1INH – presentation of clinical cases: Thomas Buttgereit, Germany
Estimated prevalence and treatment patterns of HAE with normal C1 inhibitor – an US perspective: Marc Riedl, USA
Discussion and Q&A
Webinar 3: Actual Treatment Approach in HAE :
A Perspective from Different Continents with a Focus on Growth and Emerging Markets (GEMS)
May 14th, 2024, 2:00 – 3:00 pm CET.
Topics and Faculty
Introduction and the Indian perspective: Ankur Jindal, India
HAE in South Africa: successes and challenges: Jonny Peter, South Africa
The Moscow region perspective on closing the unmet needs in HAE Medical Care: Daria Formina, Russia
The Brazilian perspective: Luis Felipe Ensina, Brazil
Discussion and Q&A
Webinar 4:
Acquired angioedema: From bench to bedside.
July 9th, 2024, 12:00 – 1:00 pm CET.
Topics and Faculty
Moderator: Dr. Jason Fok, Australia
Welcome and Introductions: Dr. Jason Fok, Australia
Introduction and association of AAE with hematological malignancies: Dr. Danny Cohn, Netherlands
Diagnosis and clinical features of AAE-C1INH: Dr. Andrea Zanichelli, Italy
Treatment of AAE-C1INH: Dr. Delphine Gobert, France
Q&A session: All faculty, moderated by Jason Fok
Webinar 5:
Dissecting Molecular and Clinical Aspects of Normal C1-INH HAE
September 18th, 2024, 12:00 – 1:00 pm CET.
Learning objectives
1. to understand the varied clinical presentations of HAE nC1INH
2. to gain insights into complex genetics of HAE nCINH
Topics & Faculty
Welcome and Introduction: Prof. Dr. Constance Katelaris, Australia
Hereditary angioedema with normal C1 inhibitor: History, meaning, types: Prof. Dr. Marc Riedl USA
New variants and the clinical differences among HAE nC1INH : Dr. Anete S. Grumach, Brazil
Genetic testing: Prof. Emeritus Anastasios E. Germenis, Greece
Q&A session: All faculty, moderated by Constance Katelaris
Webinar 6:
PEDIGREES IN HEREDITARY ANGIOEDEMA
November 12th, 2024, 2:00 – 3:00 pm CET.
Learning objectives
In this webinar, we delve into the importance and intricate process of constructing pedigrees for patients diagnosed with Hereditary Angioedema (HAE).
Join us as we explore the indispensable role of pedigrees in identifying familial patterns of HAE and learn practical strategies for effectively screening families.
Faculty & Topics
Welcome and Introduction (5 minutes)
Carolina Vera Ayala
Charité –Universitätsmedizin Berlin, Institute of Allergology,
Berlin, Germany
Constructing pedigrees for patients diagnosed with Hereditary Angioedema (HAE): History (15 minutes)
Dr. Andreas Recke
Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
Clinical genetics (15 minutes)
Dr. Gašper Markelj
Ljubljana University Medical Centre, Ljubljana, Slovenia
What to do before and what to expect at an appointment with a genetic counselor? (15 minutes)
Dr. Roger Colobran Oriol
Hospital Universitari Vall d’Hebron (HUVH), Vall d’Hebron Institut
de Recerca (VHIR), Jeffrey Modell Foundation Diagnostic and
Research Center for Primary Immunodeficiencies (Barcelona), Spain
Webinar 7: ADVANCEMENTS IN GENE THERAPIES: FOCUS ON CRISPR AND HEREDITARY ANGIOEDEMA TREATMENT
MARCH 20TH, 2025 | 10:00-11:00 am CET
Applied for accreditation EACCME® with 1 CME Point
Agenda:
Welcoming words and introduction
Prof. Dr. Costance Katelaris
Western Sydney University & Campbelltown Hospital, Sydney, Australia
TALK 1: The Current HAE Treatment Landscape: How and where does gene editing of (pre)kallikrein fit?
Prof. Dr. Marc Riedl
University of California, San Diego, California, USA
TALK 2: CRISPR technology: what is it and how does it work?
Prof. Dr. Danny Cohn
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
TALK 3: Results from the clinical trials in HAE using CRISPR technology so far and the current status
Hon. Associate Professor Dr. Hilary Longhurst
University of Auckland and Department of Immunology, Auckland City Hospital, New Zealand
Closing remarks
Prof. Dr. Constance Katelaris
Western Sydney University & Campbelltown Hospital, Sydney, Australia